Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon

Journal of Viral Hepatitis

Volumn 22, Issue 3, 2015, Pages 318-327

  Boglione, L ^a   Cusato, J ^a   De Nicolo A ^a   Cariti, G ^a   Di Perri, G ^a   D'Avolio, A ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

CYP27B1 polymorphism; HBV genotype; hepatitis B treatment; PEG interferon therapy; vitamin D

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; CALCIDIOL 1 MONOOXYGENASE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYP27B1 GENE; FEMALE; FOLLOW UP; GENE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; RELAPSE; RETROSPECTIVE STUDY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BLOOD; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84923209977     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12288     Document Type: Article

References (54)

1. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
2. Locarnini S,. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (Suppl. 1): 3-10.
3. Feld JJ, Wong DK, Heathcote EJ,. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 49: S96-S102.
4. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
5. EASL. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
6. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J,. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
7. Fung SK, Lok AS,. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40: 790-792.
8. Wong SN, Lok AS,. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12.
9. Boglione L, Cusato J, Allegra S, et al,. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 2014; 102: 35-43.
10. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C,. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11: 344-349.
11. Lee P, Eisman JA, Center JR,. Vitamin D deficiency in critically ill patients. N Engl J Med 2009; 360: 1912-1914.
12. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al,. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010; 340: b5500.
13. D'Avolio A, Ciancio A, Siccardi M, et al,. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 2011; 54: 2278-2279.
14. D'Avolio A, Ciancio A, Siccardi M, et al,. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther Drug Monit 2012; 34: 722-728.
15. Petta S, Camma C, Scazzone C, et al,. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2009; 51: 1158-1167.
16. Bitetto D, Fabris C, Falleti E, Toniutto P,. Vitamin D deficiency and HCV chronic infection: what comes first? J Hepatol 2011; 55: 944-945; author reply 5.
17. Yano M, Ikeda M, Abe K, et al,. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 2007; 51: 2016-2027.
18. Arteh J, Narra S, Nair S,. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624-2628.
19. Targher G, Bertolini L, Scala L, et al,. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-524.
20. Lange CM, Bojunga J, Ramos-Lopez E, et al,. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-893.
21. Zeljic K, Supic G, Stamenkovic Radak M, Jovic N, Kozomara R, Magic Z,. Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J Oral Pathol Med 2012; 41: 779-787.
22. Bailey R, Cooper JD, Zeitels L, et al,. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007; 56: 2616-2621.
23. Lopez ER, Zwermann O, Segni M, et al,. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol 2004; 151: 193-197.
24. Zhu Q, Li N, Han Q, et al,. Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection. Genet Test Mol Biomarkers 2012; 16: 1115-1121.
25. Rijckborst V, Hansen BE, Ferenci P, et al,. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011.
26. Rijckborst V, Hansen BE, Cakaloglu Y, et al,. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461.
27. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL,. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
28. D'Avolio A, Ciancio A, Siccardi M, et al,. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther Drug Monit 2012; 34: 165-170.
29. D'Avolio A, Cusato J, Calcagno A, Di Perri G,. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring? J Hepatol 2013; 59: 633-634.
30. D'Avolio A, De Nicolo A, Cusato J, et al,. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Res 2013; 100: 114-119.
31. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
32. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
33. Holmes JA, Nguyen T, Ratnam D, et al,. IL28B genotype is not useful for predicting treatment outcome in asian chronic hepatitis b patients treated with pegylated-interferon-alpha. J Gastroenterol Hepatol 2013; 28 (5): 861-6.
34. Lampertico P, Vigano M, Cheroni C, et al,. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2013; 57 (3): 890-6.
35. Sonneveld MJ, Wong VWS, Woltman AM, et al,. Polymorphisms at RS12979860 and RS12980275 near IL28B predict serological response to (PEG-)interferon in HBEAG-positive chronic hepatitis B. J Hepatol 2012; 54: S32-S.
36. Fisher L, Fisher A,. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513-520.
37. Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, Kockum I,. Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum Genet 2010; 18: 1349-1352.
38. Schafer A, Emmert S, Kruppa J, et al,. No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. Arch Dermatol Res 2012; 304: 353-361.
39. Bikle D,. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94: 26-34.
40. White JH,. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 2012; 13: 21-29.
41. Jones G, Strugnell SA, DeLuca HF,. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-1231.
42. Franzese O, Kennedy PT, Gehring AJ, et al,. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-3328.
43. Stoop JN, van der Molen RG, Baan CC, et al,. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778.
44. Overbergh L, Stoffels K, Waer M, Verstuyf A, Bouillon R, Mathieu C,. Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. J Clin Endocrinol Metab 2006; 91: 3566-3574.
45. Ramos-Lopez E, Bruck P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K,. CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. J Steroid Biochem Mol Biol 2007; 103: 807-810.
46. Erhardt A, Gobel T, Ludwig A, et al,. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol 2009; 81: 1716-1720.
47. Lin CL, Kao JH,. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 (Suppl. 1): 123-130.
48. Couchman L, Benton CM, Moniz CF,. Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry: the devil is in the detail. Clin Chim Acta 2012; 413: 1239-1243.
49. Shah I, James R, Barker J, Petroczi A, Naughton DP,. Misleading measures in Vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars. Nutr J 2011; 10: 46.
50. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF,. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
51. Holick MF,. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-1688S.
52. Plum LA, DeLuca HF,. The functional metabolism and molecular biology of vitamin D action. Clin Rev Bone Miner Metab 2009; 7: 20-41.
53. Ross AC, Manson JE, Abrams SA, et al,. The 2011 dietary reference intakes for calcium and vitamin D: what dietetics practitioners need to know. J Am Diet Assoc 2011; 111: 524-527.
54. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al,. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.